title: Prognostic significance of p53 immunostaining in epithelial ovarian cancer.
abstract: OBJECTIVE
  To evaluate the prognostic significance of p53 expression in epithelial ovarian cancer, including a subset of stage I patients, and to look for correlations between p53 expression and other disease parameters, including stage, grade, age, histologic subtype, second-look results, ploidy, and percent S phase.
  
  
  METHODS
  We analyzed p53 expression in 284 patients with epithelial ovarian cancer using immunohistochemical techniques in paraffin-embedded specimens. There were 36 patients with stage I disease, 20 with stage II disease, 186 with stage III disease, and 42 with stage IV disease.
  
  
  RESULTS
  p53 immunoreactivity was present in 177 cases (62%). p53 expression was associated with grade 3 to 4 disease (P = .003). The following factors were associated with a decrease in overall survival in a univarate analysis: stage III or IV disease (P = .0001), grade 3 or 4 disease (P = .0001), age above the median (P = .0002), and p53 reactivity (P = .04). In a multivariate analysis, stage, grade, and age retained independent prognostic significance. In the subset of 36 stage I patients, p53 positively approached statistical significance (P = .10) as a negative prognostic factor in a univariate analysis.
  
  
  CONCLUSIONS
  Abnormalities of p53 expression occur commonly in epithelial ovarian cancer. Although associated with decreased survival in a univariate analysis, this biologic marker did not retain independent prognostic significance in a multivariate analysis. p53 expression should be studied in a larger cohort of early-stage patients, where accurate prognostic information is needed to direct therapy.
authors.affiliation: Department of Oncology, Mayo Clinic, Rochester, MN 55905.
authors.forename: L C
authors.initials: LC
authors.lastname: Hartmann
authors.forename: K C
authors.initials: KC
authors.lastname: Podratz
authors.forename: G L
authors.initials: GL
authors.lastname: Keeney
authors.forename: N A
authors.initials: NA
authors.lastname: Kamel
authors.forename: J H
authors.initials: JH
authors.lastname: Edmonson
authors.forename: J P
authors.initials: JP
authors.lastname: Grill
authors.forename: J Q
authors.initials: JQ
authors.lastname: Su
authors.forename: J A
authors.initials: JA
authors.lastname: Katzmann
authors.forename: P C
authors.initials: PC
authors.lastname: Roche
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D015870:Gene Expression; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D013223:Statistics as Topic; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: D016159:Tumor Suppressor Protein p53